Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 7/20 | 0.64 |
| ▸ | ECE1 | P42892 | 6/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | MPO | P05164 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.59 |
| ▸ | IL1RN | P18510 | 7/20 | 0.59 |
| ▸ | ERAP1 | Q9NZ08 | 3/20 | 0.59 |
| ▸ | ACE | P12821 | 2/20 | 0.58 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30051718 | 1.00 | ERAP2 (0.64) | ERAP2ECE1KDM4EMAPTMEN1 | |
| SCHEMBL29538468 | 0.94 | ERAP2 (0.69) | ERAP2ECE1KDM4EMAPTMEN1 | |
| SCHEMBL30051546 | 0.93 | ERAP2 (0.73) | ERAP2ECE1IL1RNERAP1ACE | |
| SCHEMBL29531276 | 0.93 | ERAP2 (0.73) | ERAP2ECE1IL1RNERAP1ACE | |
| SCHEMBL29531545 | 0.93 | ERAP2 (0.73) | ERAP2ECE1IL1RNERAP1ACE | |
| SCHEMBL30051359 | 0.93 | ACE (0.64) | ERAP2ECE1KDM4EMAPTMEN1 | |
| SCHEMBL30051545 | 0.92 | ECE1 (0.65) | ERAP2ECE1KDM4EMAPTMEN1 | |
| SCHEMBL30050850 | 0.92 | ECE1 (0.65) | ERAP2ECE1IL1RNERAP1ACE | |
| SCHEMBL7622341 | 0.92 | ECE1 (0.70) | ERAP2ECE1KDM4EMAPTMEN1 | |
| SCHEMBL30991071 | 0.92 | ECE1 (0.70) | ERAP2ECE1KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023207107-A1 | GLP-1/GCG RECEPTOR CO-AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF | 苏州星洲生物科技有限公司 | 2023-11-02 | — | — | WO | claimed |
| WO-2023139106-A2 | LONG-ACTING GIPR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2023-07-27 | — | — | WO | claimed |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | claimed |
| CN-115916812-A | GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2023-04-04 | — | — | CN | claimed |
| EP-4126920-A2 | GIF RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | claimed |
| WO-2023207107-A1 | GLP-1/GCG RECEPTOR CO-AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING SAME AND USE THEREOF | 苏州星洲生物科技有限公司 | 2023-11-02 | — | — | WO | disclosed |
| WO-2023139106-A2 | LONG-ACTING GIPR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2023-07-27 | — | — | WO | disclosed |
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-05-11 | — | — | US | disclosed |
| CN-115916812-A | GIP receptor agonist peptide compounds and uses thereof | 武田药品工业株式会社 | 2023-04-04 | — | — | CN | disclosed |
| EP-4126920-A2 | GIF RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2023-02-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143604-A1 | QW DOSING OF GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, GRPR | ERAP2 552/4885ECE1 1643/4885KDM4E 4782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.